中国晚期黑色素瘤患者抗癌治疗和预后因素的实际临床结果

IF 0.3 Q4 ONCOLOGY
C. Cui, Xieqiao Yan, Ben Li, L. Si, C. Zhihong, X. Sheng, B. Lian, Xuan Wang, L. Mao, B. Tang, Li Zhou, X. Bai, Si-ming Li, Jun Guo
{"title":"中国晚期黑色素瘤患者抗癌治疗和预后因素的实际临床结果","authors":"C. Cui, Xieqiao Yan, Ben Li, L. Si, C. Zhihong, X. Sheng, B. Lian, Xuan Wang, L. Mao, B. Tang, Li Zhou, X. Bai, Si-ming Li, Jun Guo","doi":"10.1097/IJ9.0000000000000097","DOIUrl":null,"url":null,"abstract":"Purpose: China has much lower 5-year survival rates among melanoma patients than Western countries. This retrospective study describes real-world clinical outcomes and prognostic factors in locally advanced/metastatic melanoma in China. Materials and methods: Adults patients with unresectable stage III or IV melanoma treated between January 1, 2014 and December 31, 2015, at the Beijing Cancer Hospital were eligible (data cutoff: December 31, 2017). The Kaplan-Meier method and Log-Rank test were used to estimate the median value of time-to-event outcomes. A Cox proportional hazards model was simulated to evaluate associations of patients’ characteristics with survival. Results: Overall, there were 221 and 116 Chinese locally advanced and/or metastatic melanoma patients were enrolled in the first line (1L) and the second line (2L) treatments, respectively. The real-world objective response rate was <10% (1L: 6.3%; 2L: 3.4%); median progression-free survival was under 4 months (1L: 3.5; 2L: 2.3); median overall survival (OS) was <1 year (1L: 10.5; 2L: 7.5) with a low 12-month OS rate (43.5% for 1L, 30.5% for 2L). Based on univariate analyses, those with Eastern Cooperative Oncology Group (ECOG) Performance Status ≥2 (vs. ECOG=0) in 1L, and 2L treatment (vs. 1L treatment) or ECOG ≥2 (vs. ECOG=1) among 1L/2L were associated with statistically significantly worse outcomes. Conclusion: The current clinical outcomes in advanced melanoma patients in China are poor. High ECOG performance score independently increase risk of death both from 1L and 2L treatments, suggesting a high unmet medical need for immunotherapy in advanced melanoma.","PeriodicalId":42930,"journal":{"name":"International Journal of Surgery-Oncology","volume":"PP 1","pages":"e97 - e97"},"PeriodicalIF":0.3000,"publicationDate":"2020-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Real-world clinical outcomes of anticancer treatments and prognostic factors in patients with advanced melanoma in China\",\"authors\":\"C. Cui, Xieqiao Yan, Ben Li, L. Si, C. Zhihong, X. Sheng, B. Lian, Xuan Wang, L. Mao, B. Tang, Li Zhou, X. Bai, Si-ming Li, Jun Guo\",\"doi\":\"10.1097/IJ9.0000000000000097\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Purpose: China has much lower 5-year survival rates among melanoma patients than Western countries. This retrospective study describes real-world clinical outcomes and prognostic factors in locally advanced/metastatic melanoma in China. Materials and methods: Adults patients with unresectable stage III or IV melanoma treated between January 1, 2014 and December 31, 2015, at the Beijing Cancer Hospital were eligible (data cutoff: December 31, 2017). The Kaplan-Meier method and Log-Rank test were used to estimate the median value of time-to-event outcomes. A Cox proportional hazards model was simulated to evaluate associations of patients’ characteristics with survival. Results: Overall, there were 221 and 116 Chinese locally advanced and/or metastatic melanoma patients were enrolled in the first line (1L) and the second line (2L) treatments, respectively. The real-world objective response rate was <10% (1L: 6.3%; 2L: 3.4%); median progression-free survival was under 4 months (1L: 3.5; 2L: 2.3); median overall survival (OS) was <1 year (1L: 10.5; 2L: 7.5) with a low 12-month OS rate (43.5% for 1L, 30.5% for 2L). Based on univariate analyses, those with Eastern Cooperative Oncology Group (ECOG) Performance Status ≥2 (vs. ECOG=0) in 1L, and 2L treatment (vs. 1L treatment) or ECOG ≥2 (vs. ECOG=1) among 1L/2L were associated with statistically significantly worse outcomes. Conclusion: The current clinical outcomes in advanced melanoma patients in China are poor. High ECOG performance score independently increase risk of death both from 1L and 2L treatments, suggesting a high unmet medical need for immunotherapy in advanced melanoma.\",\"PeriodicalId\":42930,\"journal\":{\"name\":\"International Journal of Surgery-Oncology\",\"volume\":\"PP 1\",\"pages\":\"e97 - e97\"},\"PeriodicalIF\":0.3000,\"publicationDate\":\"2020-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Surgery-Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1097/IJ9.0000000000000097\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Surgery-Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/IJ9.0000000000000097","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 1

摘要

目的:中国黑色素瘤患者的5年生存率远低于西方国家。本回顾性研究描述了中国局部晚期/转移性黑色素瘤的真实临床结果和预后因素。材料和方法:纳入2014年1月1日至2015年12月31日在北京肿瘤医院接受治疗的无法切除的III期或IV期黑色素瘤成人患者(数据截止日期:2017年12月31日)。Kaplan-Meier法和Log-Rank检验用于估计事件发生时间结局的中位数。模拟Cox比例风险模型来评估患者特征与生存的关系。结果:总体而言,分别有221名和116名中国局部晚期和/或转移性黑色素瘤患者入组一线(1L)和二线(2L)治疗。真实世界客观有效率<10% (1L: 6.3%;2 l: 3.4%);中位无进展生存期低于4个月(1L: 3.5;2 l: 2.3);中位总生存期(OS) <1年(1L: 10.5;2L: 7.5), 12个月OS率低(1L为43.5%,2L为30.5%)。基于单因素分析,在1L组中ECOG表现状态≥2 (vs. ECOG=0),在1L/2L组中接受2L治疗(vs. 1L治疗)或ECOG≥2 (vs. ECOG=1)的患者预后较差,具有统计学意义。结论:目前中国晚期黑色素瘤患者的临床预后较差。高ECOG表现评分独立地增加了1L和2L治疗的死亡风险,表明晚期黑色素瘤免疫治疗的医疗需求未得到满足。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Real-world clinical outcomes of anticancer treatments and prognostic factors in patients with advanced melanoma in China
Purpose: China has much lower 5-year survival rates among melanoma patients than Western countries. This retrospective study describes real-world clinical outcomes and prognostic factors in locally advanced/metastatic melanoma in China. Materials and methods: Adults patients with unresectable stage III or IV melanoma treated between January 1, 2014 and December 31, 2015, at the Beijing Cancer Hospital were eligible (data cutoff: December 31, 2017). The Kaplan-Meier method and Log-Rank test were used to estimate the median value of time-to-event outcomes. A Cox proportional hazards model was simulated to evaluate associations of patients’ characteristics with survival. Results: Overall, there were 221 and 116 Chinese locally advanced and/or metastatic melanoma patients were enrolled in the first line (1L) and the second line (2L) treatments, respectively. The real-world objective response rate was <10% (1L: 6.3%; 2L: 3.4%); median progression-free survival was under 4 months (1L: 3.5; 2L: 2.3); median overall survival (OS) was <1 year (1L: 10.5; 2L: 7.5) with a low 12-month OS rate (43.5% for 1L, 30.5% for 2L). Based on univariate analyses, those with Eastern Cooperative Oncology Group (ECOG) Performance Status ≥2 (vs. ECOG=0) in 1L, and 2L treatment (vs. 1L treatment) or ECOG ≥2 (vs. ECOG=1) among 1L/2L were associated with statistically significantly worse outcomes. Conclusion: The current clinical outcomes in advanced melanoma patients in China are poor. High ECOG performance score independently increase risk of death both from 1L and 2L treatments, suggesting a high unmet medical need for immunotherapy in advanced melanoma.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
8
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信